Sunitinib plus docetaxel and trastuzumab as first-line therapy for HER2+advanced breast cancer

被引：1
|
作者：
Cardoso, F. [1 ]
Canon, J. L. [2 ]
Amadori, D. [3 ]
Dirix, L. [4 ]
Villa, E. [5 ]
Aldrighetti, D. [5 ]
Machiels, J. P. [6 ]
Verkh, L. [7 ]
Kern, K. [7 ]
Giorgetti, C. [8 ]
机构：
[1] Inst Jules Bordet, Dept Med Oncol, B-1000 Brussels, Belgium
[2] Grand Hop Charleroi, Dept Hematol Oncol, Charleroi, Belgium
[3] IRST, Meldola, Italy
[4] AZ ST Augustinus, Iridium Kankernetwerk, Antwerp, Belgium
[5] IRCCS Fdn San Raffaele Monte Tabor, Unita Operat Oncol Med, Milan, Italy
[6] Clin Univ St Luc, Ctr Canc, Univ Catholique Louvain, B-1200 Brussels, Belgium
[7] Pfizer Oncol, Dev, La Jolla, CA USA
[8] Pfizer Oncol, Dev, Milan, Italy
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)70967-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：283 / 283
页数：1
相关论文
共 50 条
  • [1] Tolerability of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2+advanced breast cancer
    Cardoso, F.
    Canon, J-L
    Amadori, D.
    Dirix, L.
    Villa, E.
    Aldrighetti, D.
    Machiels, J-P
    Verkh, L.
    Huang, X.
    Giorgetti, C.
    CANCER RESEARCH, 2009, 69 (02) : 286S - 287S
  • [2] An Exploratory Study of Sunitinib (SU) Plus Docetaxel (D) and Trastuzumab (T) for First-Line Therapy of HER2+Advanced Breast Cancer (ABC).
    Dirix, L.
    Canon, J. L.
    Amadori, D.
    Villa, E.
    Aldrighetti, D.
    Machiels, J. P.
    Verkh, L.
    Bouko, Y.
    Kem, K.
    Giorgetti, C.
    Cardoso, F.
    CANCER RESEARCH, 2009, 69 (24) : 852S - 853S
  • [3] An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer
    Cardoso, Fatima
    Canon, Jean-Luc
    Amadori, Dino
    Aldrighetti, Daniela
    Machiels, Jean-Pascal
    Bouko, Yasmina
    Verkh, Lev
    Usari, Tiziana
    Kern, Kenneth A.
    Giorgetti, Carla
    Dirix, Luc
    BREAST, 2012, 21 (06): : 716 - 723
  • [4] Everolimus plus trastuzumab and paclitaxel as first-line therapy in women with HER2+advanced breast cancer: Overall survival results from BOLERO-1
    Yardley, D.
    Hurvitz, S.
    Jiang, Z-F
    Toi, M.
    Burris, H.
    Buyse, M.
    Slamon, D.
    Makhson, A.
    Elsaid, A.
    Lerzo, G.
    Hellerstedt, B.
    Nuzzo, F.
    Sohn, J.
    Manzyuk, L.
    Cabaribere, D.
    Lincy, J.
    Weimann, A.
    Noel-Baron, F.
    Pacaud, L.
    Andre, F.
    CANCER RESEARCH, 2017, 77
  • [5] Evaluation of trastuzumab, docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer
    Wardley, A.
    Anton-Torres, A.
    Pivot, X.
    Morales-Vasquez, F.
    Dias, Zetina L.
    Gaui, M.
    Otero Reyes, D.
    Jassem, J.
    Button, P.
    Bell, R.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S33 - S33
  • [6] Trastuzumab deruxtecan for HER2+advanced breast cancer
    Lee, Jiyun
    Park, Yeon Hee
    FUTURE ONCOLOGY, 2021, 18 (01) : 7 - 19
  • [7] Trastuzumab plus Capecitabine and Docetaxel as First-line Therapy for HER2-positive Metastatic Breast Cancer: Phase II Results
    Michalaki, Vasiliki
    Fotiou, Stylianos
    Gennatas, Spyridon
    Gennatas, Constantine
    ANTICANCER RESEARCH, 2010, 30 (07) : 3051 - 3054
  • [8] Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer
    Wardley, Andrew M.
    Pivot, Xavier
    Morales-Vasquez, Flavia
    Zetina, Luis M.
    Dias Gaui, Maria de Fatima
    Reyes, Douglas Otero
    Jassem, Jacek
    Barton, Claire
    Button, Peter
    Hersberger, Veronica
    Torres, Antonio Anton
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) : 976 - 983
  • [9] Subcutaneous Trastuzumab Combined with Pertuzumab and Docetaxel as First-line Treatment of Advanced HER2-positive Breast Cancer
    Stefanou, Dimitra
    Kokkali, Stefania
    Tripodaki, Elli-Sophia
    Drizou, Maria
    Magou, Elpida
    Zylis, Dimosthenis
    Prevezanou, Maria
    Kapiris, Matthaios
    Nasi, Despoina
    Ntokou, Anna
    Dede, Mary
    Ardavanis, Alexandros
    ANTICANCER RESEARCH, 2018, 38 (11) : 6565 - 6569
  • [10] Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study
    Wardley, A.
    Anton-Torres, A.
    Pivot, X.
    Morales-Vasquez, F.
    Zetina, L.
    Dias Gaui, M. da Fatima
    Reyes, D. Otero
    Jassem, J.
    Button, P.
    Bell, R.
    EJC SUPPLEMENTS, 2008, 6 (07): : 109 - 110
12345